SPEAKERS

Tip: use Ctrl + F (or Command + F on Mac) to look for a specific speaker

RICK DOBLIN, PhD

Development of MDMA-assisted Psychotherapy for PTSD

JANIS PHELPS, PhD

Training Future Psychedelic Therapists

Matthew Johnson

MATTHEW JOHNSON, PhD

Psilocybin-occasioned mystical experiences

BIA LABATE, PhD

Panel: Diversity, Equity and Access in Psychedelic Medicine

BEN SESSA, MD

MDMA-assisted psychotherapy for alcoholism

Michael Mithoefer

MICHAEL MITHOEFER, MD

MDMA-assisted psychotherapy for PTSD: updates & observations

Fernanda Palhano Xavier de Fontes

FERNANDA PALHANO-FONTES, PhD

Findings from a randomized controlled trial with ayahuasca for treatment-resistant depression.

TORSTEN PASSIE, MD, PhD

Low-Dose Psycholytic Therapy: A Neglected Approach?

Tania re

TBA

MONNICA WILLIAMS, PhD

Panel: Diversity, Equity and Access in Psychedelic Medicine

KATRIN PRELLER, PhD

Psilocybin induces time-dependent changes in global brain connectivity

Alexander Belser

ALEXANDER BELSER, PhD

Psychedelic Therapy for Gender and Sexual Minorities

Christopher Timmermann

CHRISTOPHER TIMMERMANN, PhD cand

DMT: Neuroscience, phenomenology and therapeutic potential

Elizabeth Nielson

ELIZABETH NIELSON, PhD

Psilocybin-Assisted Treatment of Alcohol Use Disorder

Amanda feilding

At the Frontier: An Introduction to the Beckley Foundation’s New Psychedelic Research Programme

WADE DAVIS, PhD

Lessons from a life-time of ethnobotanical research

Francisco Moreno

FRANCISCO MORENO, MD

Psilocybin versus placebo in Treatment Resistant OCD

NEILOUFAR FAMILY, PhD

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Low Dose Lysergic Acid Diethylamide (LSD) in Healthy Volunteers

LEOPARDO YAWA BANE

The uses of Nixi pae in the Huni Kui tradition

Enzo Tagliazucchi

ENZO TAGLIAZUCCHI, PhD

Neural and psychological correlates of inhaled DMT in naturalistic settings

Matthew Jackson

MATTHEW JACKSON

Patient Perspectives from a Psilocybin for Depression Trial

LEOR ROSEMAN, PhD

Prophetic-Like Events in Ayahuasca Rituals with Palestinians and Israelis

Jordan Sloshower

JORDAN SLOSHOWER, MD

Psilocybin-assisted therapy of MDD using Acceptance and Commitment Therapy

RosalinD watts, PHD

Panel: Therapeutic Frameworks

Gabby Agin-Liebes

GABBY AGIN-LIEBES, PhD c.

Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer

DANIELA PELUSO, PhD

The emergence of global ayahuasca

IDO HARTOGSOHN, PhD

Psychedelics, Set and setting, Meaning-Enhancement and Placebo Response

RONAN LEVY, JD

Panel: Mainstreaming Psychyedelics

Alan Kooi Davis

ALAN KOOI DAVIS, PhD

Psychedelic-occasioned decreases in trauma among people of color

MENDEL KAELEN, PhD

Music for/as Psychedelic Therapy

LIANA SANANDA GILLOOLY

Panel: Medicalization of Psychedelics

Ofelia orlanda yolanda mendez altamirano

Curing as a Whole Organism: Mazatec culture

Lucas de Oliveira Maia

LUCAS DE OLIVEIRA MAIA, PhD

Therapeutic effects of ayahuasca by people facing severe physical illness

Emmanuelle A. D. Schindler

EMMANUELLE SCHINDLER, MD, PhD

Effects of Low Oral Dose of Psilocybin in Migraines

ADAM ARONOVICH, PhD cand

Ayahuasca as Relational Medicine

NADIA HUTTEN, PhD cand

Cognitive and subjective effects of LSD in a placebo-controlled study

MALIN UTHAUG, PhD cand

A placebo-controlled study of ayahuasca on mental health in a naturalistic setting

DAAN KEIMAN, MA

Integrating Interfaith Spiritual Care Into Psychedelic Therapies and Science

RICARDA EVENS, PhD

The Afterglow Inventory (AGI) – a new instrument to measure subacute effects of the psychedelic experience

Pedram dara

Personal experiences with MDMA-assisted psychotherapy for PTSD

Tobias Buchborn

TOBIAS BUCHBORN, PhD cand

Introduction to the pharmacodynamics of repeated psychedelic-drug intake

Luís Fernando Tófoli

LUIS F. TOFOLI, MD, PhD

An interdisciplinary discussion on the integration of the psychedelic experience

Eric Sienknecht, Psy.D. and Veronika Gold, MFT

ERIC SIENKNECHT, PsyD & VERONIKA GOLD, MFT

Ketamine-Assisted Psychotherapy: Observations

Inti garcÍa flores

Curing as a Whole Organism: Mazatec culture

Michelle Baker Jones

MICHELLE BAKER JONES

Psilocybin treatment for depression – inside perspectives

Henry J Whitfield

HENRY J WHITFIELD, MSc

A longitudinal multiple baseline investigation of psychedelic integration using ACT

AIDAN LYON, PhD

A unified, philosophical account of the mind-revealing effects of psychedelics and meditation

Timo Torsten Schmidt

TIMO TORSTEN SCHMIDT, PhD

fMRI studies of non-pharmacologically induced altered states of consciousness:

Ruben Laukkonen

RUBEN LAUKKONEN, PhD

The phenomenology of truth: How the feeling of insight guides decisions under uncertainty

Eduardo Schenberg

EDUARDO SCHENBERG, PhD

Antes o cérebro não existia (Once, the brain did not exist)

David Nicolas Langlitz

NICOLAS LANGLITZ, PhD

The Paradoxes of Psychedelic Humanities

Natasha L Mason

NATASHA L MASON, PhD cand

Acute effects of psilocybin on glutamate, functional connectivity & subjective state

Olivia Rose Marcus

OLIVIA ROSE MARCUS, PhD c.

Traditionalizing global forms: ethics in vegetalista practices of the Peruvian Amazon

HELLE KAASIK, PhD

Varieties of chemical composition of Ayahuasca.

BALAZS SZIGETI, PhD

Beyond the placebo? An exploration of psychedelics microdosing with self-blinding methodology

Raquel bennett, pSY. d

Panel: Clinical Uses of Ketamine

NICOLE AMADA

Narrative Self and the Psychedelic Experience: An exploratory qualitative study

PETER GASSER, MD

The Development of Psycholytic / Psychedelic Therapy

ANNE WAGNER, PhD

Panel: Therapeutic frameworks

Michiel van elk

MICHIEL VAN ELK, PhD

Effects of Psilocybin Microdosing on Awe and Aesthetic Experiences

Tomas Palenicek

TOMAS PALENICEK, MD, PhD

Expedition Neuron: a journey towards the neurobiology of ayahuasca in a naturalistic setting

TAYLOR LYONS, PhD cand.

The acute and long-term effects of psilocybin in healthy volunteers

Erik davis, PhD

Panel: Mainstreaming Psychedelics

IDO SIEMION, PhD

The Hakomi Method in Psychedelic Therapy: Principles and Interventions

TIM READ, MD

The Dark Place: a comprehensive model for psychedelic psychotherapy

DAVID DUPUIS, PhD

The socialization of hallucinations

JEFFREY GUSS, MD

Psilocybin-assisted therapy of depressive disorder using ACT as a therapeutic frame

Vincent Verroust

VINCENT VERROUST, PhD cand

The first clinical trials of psilocybin in France (1956-1960)

SIMON RUFFELL, MD

Modulatory Effects of Ayahuasca on Personality Structure in an Adapted Traditional Framework

CAMILLA DAY, MD

Compassion Experience Scale in Psilocybin for Treatment Resistant Depression

MARC TUTERS, PhD

Subcultural Bad Tripping: How Fear, Clarity, Power and Disgust Unite the Cosmic Right Online

JOS TEN BERGE, PhD

Drugs in Art: Instant Inspiration or Placebo?

Anja Katharina Loizaga-Velder

ANJA LOIZAGA-VELDER, PhD

The contribution of indigenous plant medicine traditions to modern psychedelic medicine

Rafael Lancelotta

RAFAEL LANCELOTTA

The Psychotherapeutic Potential of Short-acting Tryptamines

Raphaël Millière

RAPHAËL MILLIÈRE, PhD cand

The Sense of Body Ownership in Drug-Induced States

Livia Goto Silva

LIVIA GOTO SILVA, PhD

Potential therapeutic effects of 5-MeO-DMT in brain insulin resistance

DAVID LUKE, PhD

Transpersonal ecodelia: Surveying psychedelically induced biophilia

LUIS FELIPE SEQUEIRA VALÊNCIO

LUIS FELIPE SEQUEIRA VALÊNCIO, PhD

The Role of Research Ethics in the “Psychedelic Renaissance”

NICOLE BUCHANAN, PhD

Panel: Diversity, Equity and Access in Psychedelic Medicine

Milan Scheidegger

MILAN SCHEIDEGGER, MD, PhD

Pharmahuasca applications for mental health

JANI PESTANA, MSc

Motivations & modalities of psychedelic substance use in Reddit’s psychonaut community

DAAN OOSTVEEN, PhD

Towards a new materialism in psychedelics studies

BENNET ZELNER, PhD

Panel: Medicalization of Psychedelics

Tehseen noorani, PHD

Panel: Medicalization of Psychedelics

MARTIN MADSEN, PhD

Five-hour fMRI mapping after oral psilocybin reveals distinct psilocin-dependent changes in resting state functional connectivity

ELIAS DAKWAR, MD

Ketamine-assisted Treatment of Substance Use Disorders

HANNES KETTNER, MSc

Learning from uncertainty: Relax your priors and trust in the unknown

Richard Zeifman

RICHARD ZEIFMAN, PhD

How Does Psilocybin Therapy Work?: Exploring Experiential Avoidance as a Mechanism of Change

Lynnette A Averill

LYNNETTE AVERILL, PhD

Psychedelic treatments for cognitive impairment, PTSD, depression among veterans

WOUTER J. HANEGRAAFF

WOUTER HANEGRAAFF, PhD

Psychedelics as Rejected Knowledge

SAM GANDY, PhD

From Egoism to Ecoism: Psychedelics & Nature Connection

INGMAR GORMAN, PhD

MDMA-assisted Psychotherapy for PTSD: Beyond Symptom Reduction

Eric vermetten, MD phd

Panels: MDMA for PTSD & Beyond Symptom Reduction

robert Schoevers, phd

Panel: Clinical Uses of Ketamine

Stephen Snelders, phd

Panel: Historical Contexts

Kim Kuypers, phd

Panels: Microdosing II & Multidisciplinary 5-MeO-DMT Research

Emilia sanabria, phd

Panel: Ayahuasca in the lab

Patricia Pisters, phd

Panels: Humanities & Mainstreaming Psychedelics

Rotem petranker, PHD(C)

Microdosing Results from the Global Drug Survey 2019

will hall, Phd (C)

Panel: Medicalization of Psychedelics

Neşe Devenot, Phd

Panel: Mainstreaming Psychedelics

Tijmen Bostoen, MD

Panels: Clinical Uses of Ketamine & Therapeutic Frameworks

flora moujaes, MA

renske eRin blom, Phd cand

Psilocybin in patients with treatment resistant

depression: first clinical experiences from a multicenter RCT